Longitudinal analysis reveals parosmia significantly enhances quality of life in C19OD, suggesting a focus for improving patient outcomes.
Independent of mental health, chemosensory function independently drives QoL in C19OD. Parosmia, low odor threshold, and patient-reported GD are all associated with poorer QoL at baseline. Longitudinally, the ability to differentiate among odors is an important correlate of improvement of smell-related QoL in C19OD patients, while parosmia is the strongest driver of longitudinal recovery of smell-related QoL in C19OD. Trending domain-specific olfactory performance in C19OD may allow for improved patient counseling and QoL prognosis.
No takes yet. Share an insight, caveat, or question.
Saak et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: